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 Glaucoma is a complex and genetically heterogeneous
disease characterized by the progressive apoptotic death of
retinal ganglion cells. This process leads to the excavation of
the optic nerve head and to progressive and irreversible visual
field loss [1,2]. Glaucoma is the second leading cause of blind-
ness with prevalence of 0.15% in the total population and of
approximately 2-4% among the population over the age of
40. Primary open-angle glaucoma (POAG) is the most com-
mon form of glaucoma, that manifests as an insidious and
chronic condition characterized by a gonioscopically open
angle. Although most people will not develop glaucomatous
damage despite having an intraocular pressure (IOP) well
above 21 mmHg, elevated IOP (>21 mmHg), originated by an
increase in aqueous outflow resistance, is the most important
risk factor in glaucoma [3]. It is speculated that elevated IOP
could compress the optic nerve at the lamina cribosa. Depend-
ing on individual susceptibility factors, elevated IOP might
damage ganglion cell axons and local glial cells as well as
impair the capillary blood supply to the region. These events
could progressively lead to the apoptotic death of ganglion
cells [4]. Other risk factors include age, gender, myopia, and
vascular and genetic factors. It has also been reported that
changes in expression of genes such as p21(WAF1/CIP1) and
14-3-3 sigma may indicate an increased risk for glaucoma [5].
Genetically, POAG shows a complex pattern of inherit-
ance with sporadic manifestations in most patients. The
myocilin (MYOC) gene is mutated in 3-5% of sporadic pa-
tients in populations around the world [6-10]. This gene is
composed of three exons and is ubiquitously expressed in many
human tissues including the iris, ciliary body, and trabecular
meshwork (TM) [11-13]. The majority of MYOC disease-caus-
ing mutations map to the olfactomedin-like domain of the pro-
tein, which is encoded by exon 3 [12]. In addition, heterozy-
gous mutations in cytochrome P450 1B1 CYP1B1, a gene in-
volved in primary congenital glaucoma, have been identified
in 4-9% of affected POAG subjects from France [14,15], In-
dia [16], and Spain [17].
The optineurin (OPTN) gene consists of sixteen exons
and the first three are noncoding. The OPTN gene is expressed
in ocular tissues such as retina, TM, and nonpigmented ciliary
epithelium [18]. Mutations in this gene predominately result
in normal tension glaucoma [18], a subtype of glaucoma fea-
tured by normal IOP, but its role in high-pressure POAG is
still controversial.
We report the first complete mutational analysis of the
promoter and coding regions of MYOC and the coding region
of the OPTN gene in Spanish patients diagnosed with adult-
onset POAG. We found in this population, disease-causing
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862mutations in the olfactomedin-like domain, encoded by the
third exon of MYOC, are present in 2.7% of sporadic POAG
cases. Our data also enable us to rule out a role of OPTN se-
quence variations in the development of POAG in Spanish
patients.
METHODS
Subjects:  One hundred and ten unrelated native Spanish pa-
tients diagnosed with POAG and forty diagnosed with OHT,
were studied retrospectively for MYOC and OPTN mutations.
The control group was composed of 98 individuals in whom
glaucoma was ruled out. All the individuals were recruited in
the Department of Ophthalmology, University Hospital of
Albacete, Spain (“Servicio de Oftalmología, Complejo
Hospitalario Universitario de Albacete”).
The following conditions were required to diagnose
POAG: exclusion of secondary causes (e.g., trauma, uveitis,
steroid-induced or neovascular glaucoma); open anterior cham-
ber angle (grade III-IV gonioscopy); IOP higher than 21
mmHg; characteristic optic disc changes; and an alteration of
the visual field, tested by automated perimetry (with
Humphrey’s perimeter). The global indices such as mean de-
viation (MD) and pattern standard deviation (PSD) of the
baseline visual fields were analyzed for all cases. All study
subjects underwent a complete ocular examination. The study
protocol was approved by the Ethics Committee for Human
Research of the University Hospital of Albacete and followed
the tenets of the Declaration of Helsinki. Informed consents
were obtained from all the study subjects.
Patients were classified as having early (MD better than -
6 dB), moderate (MD between -6 and -12 dB), or severe (MD
worse than -12 dB) visual field alteration according to the clas-
sification by Hodapp et al. [19]. Medical treatment primarily
included topical beta-blockers and prostaglandin analogues.
Sequence variation screening:  Genomic DNA was ex-
tracted from the peripheral leukocytes of all studied subjects
with the Perfect gDNA Blood Mini kit (Eppendorf, Madrid,
Spain) according to the manufacturer’s protocol. The promoter
(nucleotides -1 to -1117) and the three exons of MYOC were
amplified using primers designed to allow analysis of splic-
ing consensus sequences (Table 1). PCRs were performed in
a 50 µl volume containing 50-100 ng of genomic DNA, 10
pmol of forward and reverse primers, 2 mM MgCl2 for exons
1 and 3, 0.5 mM MgCl2 for exon 2, 100 µM of each dNTP,
and 1 U of Taq DNA polymerase (Biotools, B&M Labs,
Madrid, Spain). Thermocycling included an initial denatur-
ation step at 94 °C for four min followed by 35 cycles of de-
naturation, annealing, and extension (Table 1). A final cycle
was performed at 72 °C for seven min. Terminator cycle se-
quencing was carried out using the BigDye® (v3.1) kit (Ap-
plied Biosystems, Foster City, CA). The products of sequenc-
ing reactions were analysed in an automated capillary DNA
sequencer (ABI Prism 3100-Avant genetic analyzer; Applied
Biosystems).
Single stranded conformational polymorphism analysis:
Mutations in the 13 coding exons (4-16) of the OPTN gene
were screened by PCR-SSCP. Each exon was amplified by
PCR in 50 µl reaction volumes using the primers, annealing
temperatures, and times detailed in Table 2. Primers were also
designed to allow analysis of splicing consensus sequences.
Each reaction contained 2.0 mM MgCl2, 10 pmol of forward
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TABLE 1. OLIGONUCLEOTIDE PRIMERS USED FOR AMPLIFICATION OF
THE MYOCILIN GENE
                                       Annealing
                                       temperature               Amplicon
                                       and time      Extension    length
 Region     Primer sequence (5'-3')    (°C/s)        time (s)      (bp)
--------   -------------------------   -----------   ---------   --------
Promoter   F: TCCAGAAAGCCTGTGAATTTGA
           R: AGGCAGGCCAGAAGCAGC         61.5/20        60         1117
Exon I     F: CTCACCAAGCCTCTGCAATG
           R: TGAACTCAGAGTCCCCCCAC       62/20          15          654
Exon II    F: ACATAGTCAATCCTTGGGCC
           R: CATGAATAAAGACCATGTGG       55/20          20          239
Exon III   F: TCTGTGTTTGGAAAGATTATGG
           R: CCTGAGCATCTCCTTCTGCC       59/30          40          890
Annealing temperature and time, extension time for each primer pair
and the predicted length for each of the PCR DNA products in base
pairs (bp) are listed. In the Primer sequence column, F indicates for-
ward and R indicates reverse.
TABLE 2. OLIGONUCLEOTIDE PRIMERS USED FOR AMPLIFICATION OF
THE OPTINEURIN GENE
                                    Annealing
                                   temperature   Extension   Amplicon
                                    and time       time       length
Exon    Primer sequence (5'-3')      (°C/s)         (s)        (bp)
----   -------------------------   -----------   ---------   --------
4      F: GCCAGTGGG TTTGTGGGAC
       R: TGCAAAGGGATGGCATTTC         60/20         20         320
5      F: CACTTTCCTGGTGTGTGACTCC
       R: AAACAACATCACAATGGATCG       60/25         20         281
6      F: CCCAGCCTTAGTTTGATCTG
       R: GGGGAGGCTTTATAGTTTGC        60/20         20         278
7      F: CATATTGTGTTAAATCCCTTGC
       R: GGTCACAACATTTGACCTCC        60/20         20         198
8      F: AGTCTTTGGAATTTTTCTGATG
       R: ATGGGTGAACTGTATGGTATC       60/30         30         287
9      F: GCTATTTCTCTTAAAGCCAAAG
       R: ACTCTCGTGTGTGTGGGTG         60/30         14         205
10     F: GAGGTTTGTTTAATGTCAGATG
       R: TCAAAGGAGGATAAAATTGC        55/30         30         211
11     F: CACTGCGACGTAAAGGAGC
       R: GCTGCCCTTCTGACTCAAC         65/30         30         231
12     F: ATATTTTCCCCAGGATTCC
       R: AACGTTCAACAGTTTCTGTTC       55/30         30         196
13     F: CAGGCAGAATTATTTCAAAAC
       R: AATACAGTCAGGGCTGGC          60/30          5         260
14     F: ACAGCACTACCTCCTCATCGC
       R: GATGTGAGCTCTGGGTCCTCC       65/30         20         231
15     F: TCAGTGTTGTCATGTTTCGGG
       R: TGAAAATCCAGGATCACACG        60/30         30         171
16     F: CCTGCAAAATGGAACTAATGG
       R: ACATTTACCAACAGTTTTGGG       61/20         15         203
Annealing temperature and time, extension time for each primer pair
and the predicted length for each of the PCR DNA products in base
pairs (bp) are listed. In the Primer sequence column, F indicates for-
ward and R indicates reverse.
TABLE 3. ELECTROPHORETIC CONDITIONS USED FOR SINGLE-STRANDED
CONFORMATIONAL POLYMORPHISM ANALYSIS
 Acrylamide/
bisacrylamide   Glycerol   Temperature   Voltage
    (10%)         (%)         (°C)         (V)
-------------   --------   -----------   -------
    49/1           0           RT          300
    29/1           5           RT          300
    29/1           0           4           600
Acrylamide/bisacrylamide and glycerol composition of the gels as
well as temperature and voltage used for electrophoresis are indi-
cated.
863and reverse primers, 100-200 µM dNTPs, 0.5 U Taq Poly-
merase (Biotools), and 50-100 ng of genomic DNA. Reac-
tions were denatured at 94 °C for four min followed by 35
cycles of denaturation, annealing, and extension (Table 2) as
well as a final extension of 72 °C for seven min. PCR prod-
ucts (2-4 µl) were added to two volumes (4-8 µl) of SSCP
stop solution consisting of 95% deionized formamide, 10 mM
EDTA, 1 mg/ml Bromophenol blue, 1 mg/ml Xylene Cyanol
(all these reagents were supplied by Sigma-Aldrich, St. Louis,
MO), were denatured at 95 °C for ten min, and were chilled
on ice for five min. The presence of abnormally migrating
bands was confirmed by three different electrophoretic condi-
tions using acrylamide gels (Table 3). Electrophoresis was
performed on a DCode™ Universal Mutation Detection Sys-
tem (Bio-Rad, Hercules, CA) in 0.5X TBE buffer (45 mM
Tris, 45 mM boric acid, 1 mM EDTA). After the run, gels
were removed from the apparatus and the DNA bands were
visualized by silver staining [20]. Mobility shift of single-strand
DNA from the normal pattern indicated the presence of a pos-
sible mutation and was further investigated by sequence analy-
sis of genomic DNA.
Linkage disequilibrium and haplotype construction:
Pairwise linkage disequilibrium (LD) between the SNPs with
minor allele frequencies (MAF) higher than 5% was measured
as D’ [21] using the Haploview software version 3.2 [22].
Regions of strong LD (LD blocks) were inferred using the
confidence-interval model proposed by Gabriel and colleagues
[23] as implemented in Haploview. Haplotype reconstruction
was done with the expectation-maximization algorithm in
PowerMarker v. 3.22 [24].
Statistical analysis:  The significance of the difference in
frequencies of DNA polymorphisms between patients and
control subjects was determined by the x2 test when all ex-
pected values were five or more. The Fisher’s exact test was
used when expected values were less than five. Data were sta-
tistically treated by using the SigmaStat 2.0 software (SPSS
Science, Inc., Chicago, IL).
Expression of mutant myocilin in 293T cells:  Myocilin
point mutations were obtained as previously described [25].
The specific PCR primers used for mutagenesis were: 5'-CCA
GAA CTG TCA TAA CAT ATG AGC TGA ATA CC-3' (for-
ward) and 5'-GGT ATT CAG CTC ATA TGT TAT GAC AGT
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Figure 1. Genomic structure of the human myocilin gene and location of identified DNA sequence variations.  The promoter and the three
exons are represented by boxes. Consensus regulatory sequences in the promoter region are depicted in the inset. Pathogenic mutations and
polymorphisms in the coding region are indicated by solid and dashed arrows, respectively. Sequence variations in the promoter region are
shown by arrowheads. Novel mutations are shown by asterisks. All mutations are defined in terms of the one-letter code. Designated features
include AP-1-like and AP-2-like sequences, putative TATA and SAC boxes, glucocorticoid response element (GRE), negative glucocorticoid
response element (nGRE), thyroid response element (TRE) and a MIR repeat [26,63]. -700_699ins: -
700_699insCAGACACACATATACATGCACATACACA.
TABLE 4. CLINICAL CHARACTERISTICS OF PARTICIPANTS IN THE STUDY
    Variable       OHT (n=40)   POAG (n=110)   Control (n=98)
----------------   ----------   ------------   --------------
Age (mean±SD)      56.5±11.9     62.2±11.4       61.1±12.6
Female (%)         47.5          48.2            51.1
Male (%)           52.5          51.8            48.9
IOP OD (mean±SD)   17.6± 4.0     17.7± 3.2       15.1± 3.1
IOP OS (mean±SD)   17.8± 4.4     17.3± 3.0       15.2± 3.1
C/D OD (mean±SD)    0.3± 0.2      0.5± 0.2        0.2± 0.2
C/D OS (mean±SD)    0.3± 0.2      0.5± 0.2        0.2± 0.2
Details of clinical features of 40 OHT, 110 POAG patients, and 98
unaffected controls are shown in the table. Since this is a retrospec-
tive study, IOP values before medical treatment were generally not
available. C/D indicates cup-disc ratio of optic nerve; OD indicates
right eye; OS indicates left eye; and SD indicates standard deviation.
The three groups were homogeneous with respect to gender and age.
Mean IOP and C/D ratios in glaucoma patients were higher than in
controls. In the “Variable” column, the listed age was at the time of
the study.
864TCT GG-3' (reverse) for Arg346Thr; 5'-CAG CAG CAT GAT
TGA CCA CAA CCC CCT GGA GAA G-3' (forward) and 5'-
CTT CTC CAG GGG GTT GTG GTC AAT CAT GCT GCT
G-3' (reverse) for Tyr479His.
Human embryonic kidney 293T cells were bought from
the American Type Culture Collection (ATCC, Rockville, MD).
Transient expression of wild-type and mutant myocilins was
performed as described [25]. An expression analysis of the
different myocilin forms was performed by western
immunoblot using an anti-myc antibody (9E10, Santa Cruz,
Valencia, CA) diluted at 1:400-1:500 [25]. Fluorescence mi-
croscopy was also carried out as described [25].
RESULTS
Phenotype of patients:  A total of 110 unrelated and sporadic
POAG patients were studied. In addition, we analyzed 40 cases
diagnosed with OHT. The control group included 98 individu-
als in whom glaucoma was ruled out. The main clinical fea-
tures of most of these subjects have been reported in a previ-
ous study of CYP1B1 mutations in Spanish patients with POAG
[17]. Subjects with mutations in the CYP1B1 gene were not
included in the present study. The three groups were homoge-
neous with respect to gender and age (p>0.1; Table 4). Pa-
tients were under medical treatment to reduce IOP. Therefore,
their IOP mean values were below 21 mmHg at the time of
the study (Table 4), which indicated that treatment was effec-
tive. The mean IOP and C/D ratios in both eyes of glaucoma
patients were significantly higher (p<0.01) than in controls
(Table 4). The visual field status of the eyes from POAG pa-
tients was severe for 12.7%, moderate for 27.4%, early for
49.6%, and normal for 7.3%. The visual field could not be
determined in 3.0% of eyes. Normal eyes were from patients
who showed monolateral visual field alterations. The visual
field was normal in the OHT patients.
Identification of myocilin sequence variations and geno-
type-phenotype correlation: Genomic DNA from each of 110
POAG and 40 OHT unrelated Spanish patients was screened
by direct PCR sequencing for mutations in the promoter (nucle-
otides -1 to -1117) and in the three exons including consensus
splicing sequences of the MYOC gene. OHT patients were
investigated because elevated IOP is one of the major risk fac-
tors for the development of glaucoma and in our group of
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TABLE 5. ALLELE FREQUENCIES OF MYOCILIN PROMOTER AND CODING
SEQUENCE VARIATIONS IN PRIMARY OPEN-ANGLE GLAUCOMA, ADULT-
ONSET OCULAR HYPERTENSION, AND CONTROL SUBJECTS
                                  POAG (%)   OHT (%)   CONTROL (%)
     Polymorphism        Allele   (n=220)    (n=80)      (n=196)      P*     P#
----------------------   ------   --------   -------   -----------   ----   ----
-1000C>G                    C       90.0       88.7        86.7      0.29   0.64
                            G       10.0       11.3        13.3
-700_699ins                WT      100.0       99.5       100.0      1.00   0.28
                            I        0.0        0.5         0.0
-387C>T                     C       89.5       88.7        86.7      0.37   0.64
                            T       10.5       11.3        13.3
-339(GT)11-19              11        0.5        0.0         0.0      0.14   0.48
                           12        9.5       16.6        16.3
                           13       34.1       40.0        40.8
                           14       27.3       15.0        19.4
                           15       27.3       26.7        22.4
                           16        1.3        0.0         1.0
                           19        0.0        1.6         0.0
-315G>A                     G      100.0       99.5       100.0      1.00   0.28
                            A        0.0        0.5         0.0
-306G>A                     G       80.5       85.0        81.6      0.80   0.53
                            A       19.5       15.0        18.4
-224T>C                     T       80.0       71.2        69.9      0.06   0.80
                            C       20.0       28.8        30.1
-190G>T                     G      100.0      100.0        99.5      0.39   0.28
                            T        0.0        0.0         0.5
-126T>C                     T       97.7       95.0        98.5      0.70   0.21
                            C        2.3        5.0         1.5
-83G>A                      G       88.2       93.7        87.8      0.90   0.10
                            A       11.8        6.3        12.2
c.250G>A (Arg76Lys)         G       89.0       95.0        89.7      0.87   0.10
                            A       11.0        5.0        10.3
c.499A>G (Leu159Leu)        A      100.0       97.5       100.0      1.00   0.08
                            G        0.0        2.5         0.0
c.520G>C (Leu166Leu)        G      100.0       98.8       100.0      1.00   0.28
                            C        0.0        1.2         0.0
c.877G>T (Thr285Thr)        G      100.0      100.0        99.5      0.47   0.28
                            T        0.0        0.0         0.5
c.997G>A (Thr325Thr)        G       99.1       98.8        99.5      1.00   0.48
                            A        0.9        1.2         0.5
c.1063T>C (Tyr347Tyr)       T       99.1       95.0        99.0      1.00   0.31
                            C        0.9        5.0         1.0
C.12145A>G (Lys398Arg)      A      100.0      100.0        99.5      0.47   0.28
                            G        0.0        0.0         0.5
The full description of -700_699ins is -
700_699insCAGACACACATATACATGCACATACACA. In the
table, I indicates the insertion allele, WT indicates the wild-type al-
lele, and n is the total number of chromosomes. The asterisk indi-
cates POAG versus controls and the sharp (hash mark) indicates OHT
versus controls.
TABLE 6. GENOTYPE FREQUENCIES OF MYOCILIN PROMOTER AND
CODING SEQUENCE VARIATIONS IN PRIMARY OPEN-ANGLE GLAUCOMA,
ADULT-ONSET OCULAR HYPERTENSION, AND CONTROL SUBJECTS
                        Allele1/   POAG (%)   OHT (%)   CONTROL (%)
    Polymorphism        Allele2    (n=110)    (n=40)      (n=98)       P*     P#
---------------------   --------   --------   -------   -----------   ----   ----
-1000C>G                  C/C        80.0       82.5      86.7        0.26   0.12
                          C/G        20.0       12.5      13.3
                          G/G         0.0        5.0       0.0
-700_699ins#             WT/WT      100.0       97.5      100.0       1.00   0.28
                         WT/I         0.0        2.5       0.0
                          I/I         0.0        0.0       0.0
-387C>T                   C/C        80.0       82.5      86.7        0.30   0.12
                          C/T        19.0       12.5      13.3
                          T/T         1.0        5.0       0.0
-339(GT)11-19            11/15        1.8        0.0       0.0        0.44   0.47
                         12/13       18.2       33.3      30.6
                         12/14        1.8        0.0       1.0
                         12/15        0.0        0.0       1.0
                         13/14       24.5       10.0      22.5
                         13/15       23.6       33.3      27.5
                         13/16        1.8        0.0       1.0
                         13/19        0.0        3.3       0.0
                         14/15       27.3       20.0      15.3
                         15/16        0.9        0.0       1.0
-315G>A                   G/G       100.0       97.5      100.0
                          G/A         0.0        2.5       0.0
                          A/A         0.0        0.0       0.0
-306G>A                   G/G        64.5       65.0      64.3        0.60   0.74
                          A/G        33.6       32.5      34.7
                          A/A         1.9        2.5       1.0
-224 T>C                  T/T        62.7       55.0      49.0        0.10   0.70
                          C/T        34.5       32.5      41.8
                          C/C         2.7       12.5      9.2
-190G>T                   G/G       100.0      100.0     99.0         0.47   1.00
                          G/T         0.0        0.0       1.0
                          T/T         0.0        0.0       0.0
-126T>C                   T/T        95.5       90.0      96.9        0.69   0.21
                          C/T         4.5       10.0      3.1
                          C/C         0.0        0.0       0.0
-83G>A                    G/G        78.1       88.1      76.5        0.94   0.24
                          A/G        21.0       11.9      22.5
                          A/A         0.9        0.0       1.0
c.250G>A (Arg76Lys)       G/G        79.0       89.0      79.6        1.00   0.27
                          A/G        20.0       11.0      19.3
                          A/A         0.9        0.0       1.0
c.499A>G (Leu159Leu)      A/A        99.0       97.5      100.0       1.00   0.28
                          A/G         1.0        2.5       0.0
                          G/G         0.0        0.0       0.0
c.520G>C (Leu166Leu)      G/G        99.0      100.0     100.0        1.00   1.00
                          G/C         1.0        0.0       0.0
                          C/C         0.0        0.0       0.0
c.877G>T (Thr285Thr)      G/G       100.0       97.5      99.0        0.47   0.20
                          G/T         0.0        2.5       1.0
                          T/T         0.0        0.0       0.0
c.997G>A (Thr325Thr)      G/G        97.0       97.5      99.0        0.62   0.47
                          G/A         3.0        2.5       1.0
                          A/A         0.0        0.0       0.0
c.1063T>C (Tyr347Tyr)     T/T        96.3       95.0      98.0        0.68   0.32
                          T/C         3.7        5.0       2.0
                          C/C         0.0        0.0       0.0
C.1215A>G (Lys398Arg)     A/A       100.0      100.0     99.0         0.47   1.00
                          A/G         0.0        0.0       1.0
                          G/G         0.0        0.0       0.0
The full description of -700_699ins is -
700_699insCAGACACACATATACATGCACATACACA. In the
table, I indicates the insertion allele, WT indicates the wild-type al-
lele, and n is the total number of chromosomes. The asterisk indi-
cates POAG versus controls and the sharp (hash mark) indicates OHT
versus controls.
865POAG patients, OHT was the first stage of the disease. The
same genetic analysis was performed in 98 control subjects.
Allele and genotype frequencies for all sequence variations
were calculated. Genotype frequencies did not deviate from
the Hardy-Weinberg equilibrium (data not shown). We identi-
fied six common SNPs (MAF >5% in at least one group) in
the promoter region: -1000C>G, -387C>T, -306G>A, -
224T>C, -126T>C, and -83G>A (Figure 1 and Table 5). Two
of them were located close to two consensus sequences: SNP
-224T>C was mapped next to the 3' end of one negative glu-
cocorticoid response element (nGRE) and SNP -83G>A was
placed at the 3' end of a SAC box (Figure 1). The two consen-
sus sequences are putatively involved in the regulation of
myocilin expression. The promoter polymorphism, -387C>T,
was located in a mammalian interspersed repeat (MIR) ele-
ment [26]. We also detected a polymorphic GT microsatellite
at position -339 (Figure 1) with seven alleles ranging from
eleven to nineteen repetitions. Alleles 11, 16, and 19 presented
the lowest frequencies in the three groups of subjects (0-1.6%)
while allele 13 was the most frequent, ranging from 34.1% in
POAG patients to 40.8% in controls (Table 5). Alleles 17 and
18 were not detected in our population. The genotype 13/15
was highly represented in the three groups and varied from
23.6% in POAG to 33.3% in OHT subjects (Table 6). This
polymorphism has been previously described in Chinese [27]
and Swedish [28] populations. We did not detect any statisti-
cally significant association between these MYOC promoter
polymorphisms and either POAG or OHT (Table 5 and Table
6). We also observed the common coding SNP, Arg76Lys, in
this population (Figure 1) with similar allele and genotype
frequencies in cases and controls (Table 5 and Table 6).
In addition, nine sequence variations with MAFs greater
than or equal to 5% were identified: -700_699ins, -315G>A, -
190G>T, c.499A>G (Leu159Leu), c.520G>C (Leu166Leu),
c.877G>T (Thr285Thr), c.997G>A (Thr325Thr), c.1063T>C
(Tyr347Tyr), and c.1215A>G (Lys398Arg; Figure 1 and Table
5). The last SNP was detected only in a control subject (Table
5 and Table 6). To the best of our knowledge two of these
SNPs (-315G>A and -190G>T) and the 28 bp insertion (-
700_699insCAGACACACATATACATGCACATACACA)
have not been previously described. They were found in two
different OHT patients (-315G>A and -700_699ins) and in
one control subject (-190G>T; Table 5 and Table 6). The 28
bp insertion was located in an AP1-like sequence (Figure 1).
Of the remaining six rare polymorphisms, five were synony-
mous mutations (Leu159Leu, Leu166Leu, Thr285Thr,
Thr325Thr, and Tyr347Tyr), while one (Lys398Arg) originated
a conservative amino acid substitution (Figure 1). All of them
except Leu166Leu have been previously reported [8,29]. As-
sociation analysis of these polymorphisms with the disease
was limited by their low frequencies (Table 5 and Table 6).
Myocilin linkage disequilibrium structure: To determine
the linkage disequilibrium (LD) structure of the MYOC gene
in our population, we evaluated in the control group pairwise
LD between all SNPs with MAF >5%. Two LD blocks were
detected (Figure 2). Block 1 comprises SNPs -1000C>G and -
387C>T (D’=1.0; D’ confidence bounds=0.88-1.0) while block
2 is composed of SNPs -83G>A and Arg76Lys (D’=0.95; D’
confidence bounds=0.80-0.99). The same LD structure was
observed in glaucoma patients (data not shown).
Haplotype analysis:  MYOC SNPs with MAF >5% were
used to construct predicted haplotypes, taking into account
only one SNP from each LD block (-1000C >G from block 1
and -83G>A from block 2). Twenty haplotypes with frequen-
cies >2% were inferred from our data, but only five exhibited
frequencies >5% in the three groups (Table 7). The rare in-
ferred haplotypes (<5%) were pooled in one class to allow
comparison between cases and controls. We did not find any
significant differences in predicted haplotype frequencies be-
tween cases and controls (Table 7), which indicates that they
do not contribute to the development of glaucoma.
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Figure 2. Pairwise linkage disequilibrium pattern of myocilin single
nucleotide polymorphisms measured by D’.  The location of each
tested SNP along the MYOC gene is indicated at the top. The strength
of LD is depicted by grey intensity, which moves from light grey to
black as D’ progresses from 0 to 1.
TABLE 7. FREQUENCIES OF MYOCILIN INFERRED HAPLOTYPES IN
PRIMARY OPEN-ANGLE GLAUCOMA, ADULT-ONSET OCULAR HYPERTEN-
SION, AND CONTROL SUBJECTS
    Haplotype        POAG (%)   OHT (%)   CONTROL (%)    p*      p#
------------------   --------   -------   -----------   -----   ----
H9  (C-13-G-T-T-G)     19.3      21.1        21.1       0.055   0.83
H7  (C-13-G-C-T-G)     14.2      21.1        20.6
H15 (C-15-A-T-T-G)     11.3      13.2        16.7
H18 (G-15-G-T-T-G)     14.6       9.2         6.1
H4  (C-12-G-T-T-G)      5.2       7.9         5.6
Rest of haplotypes     35.4      27.6        30.0
Haplotypes were constructed with polymorphisms, -1000, -
339(GT)11-19, -306, -224, -126 and -83. Predicted haplotypes with
frequencies lower than 2% were not considered. Only haplotypes
with frequencies higher than 5% in all groups are shown. The aster-
isk indicates POAG versus controls and the sharp (hash mark) indi-
cates OHT versus controls.
866Identification of myocilin pathogenic mutations in spo-
radic primary open-angle glaucoma cases: One non-sense
(Gln368stop) and two missense (Ala445Val and Tyr479His)
mutations were identified in three POAG patients (2.7%; Fig-
ure 1 and Table 8). All of them were present in heterozygosis
and affected amino acid positions located in the olfactomedin-
like domain (exon 3) of myocilin. Two of these mutations
(Gln368Stop and Ala445Val) were previously reported in
POAG [8,30] and as far as we know, the third mutation
(Tyr479His) has been detected for the first time in the present
study. Ages at diagnosis ranged from 32 to 56 years in this
group of POAG patients (mean of 51.6 years; Table 8). In our
sample, the mutation Gln368Stop (patient number 67) was
associated with a severe phenotype featured by severe visual
field alteration, high optic disk excavation, and resistance to
medical treatment, which requires filtration surgery for an
adequate control of IOP (Table 8). Carriers of mutations
Ala445Val (patient number 50) and Tyr479His (patient num-
ber 3) showed early alteration of the visual field and their IOPs
were adequately controlled with drugs (Table 8). The
Tyr479His mutation was associated with an early-onset of the
disease (32 years). Additionally, we also found the novel
myocilin mutation Arg346Thr in patient number 19 who was
diagnosed with glaucoma at 44 years and showed a narrow-
angle (Table 8). Due to the narrow-angle, this patient was not
included in the group of POAG subjects carrying MYOC mu-
tations. After diagnosis, this subject underwent Nd:YAG laser
iridotomy to prevent acute angle-closure glaucoma followed
by treatment with three drugs (pilocarpine, dorzolamide, and
timolol) to reduce IOP. In spite of this treatment, he required
filtration surgery for the correct control of IOP. After 22 years
of evolution, this patient displayed an extreme clinical pheno-
type characterized by bilateral and severe visual field alter-
ation and large C/D ratios (Table 8).
Evaluation of the two novel myocilin mutations pathoge-
nicity by multiple sequence alignment and transient expres-
sion in 293T cells:  We used three approaches to evaluate the
pathogenicity of the novel mutations: (a) analysis of evolu-
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Figure 3. Multiple amino acid sequence alignment of myocilin from different species.  Sequence alignment was generated by ClustalW.
Residues affected by mutations are indicated by arrowheads. Asterisks indicate amino acid positions at which all query sequences are identi-
cal. Amino acid positions at which all analyzed sequences have amino acids that are chemically similar are denoted by two dots (:). One dot
denotes amino acid positions with weak chemical similarity (.). Arrows indicated regions of the polypeptide chain which are predicted to fold
into a beta-sheet conformation.
TABLE 8. CLINICAL FEATURES OF GLAUCOMA PATIENTS WITH PATHOGENIC MYOCILIN MUTATIONS
                                                                                 Visual                    Treatment
                         Age at the                          IOP       C/D       field                     (number of
               Subject    time of      Age at               OD/OS     Ratio    alteration   Iridocorneal    drugs)/
  Mutation     number    the study    diagnosis   Gender   (mmHg)    (OD/OS)    (OD/OS)        angle        surgery
------------   -------   ----------   ---------   ------   -------   -------   ----------   ------------   ----------
R346T*           19          66          44         M       10/10    0.9/0.7    Severe/         1/2          3/Yes
(c.1059 G>C)                                                                    severe
Q368Stop         67          68          56         M       20/16    0.9/0.9    Severe/          4           2/Yes
(c.1124C>T)                                                                     severe
A445V            50          72          67         F       15/15     ND/ND     Early/           4           2/No
(c.1356 C>T)                                                                    early
Y479H*            3          40          32         M       14/16    0.4/0.4    Early/           4           1/No
(c.1457 T>C)                                                                    early
Mutation information was based on the MYOC GenBank accession number: NM_000261. IOP values were obtained following medical
treatment. IOP records before treatment were not always available. The asterisk indicates novel mutations. IOP: intraocular pressure, OD:
right eye, OS: left eye, C/D: cup-disc ratio of optic nerve, ND: not determined due to oblique insertion of the optic nerve head.
867tionary conservation of affected amino acids; (b) prediction
of physicochemical changes induced by the different muta-
tions; and (c) study of expression and subcellular distribution
of cloned mutant and wild-type myocilin in transiently trans-
fected 293T cells. Comparison of amino acid sequence align-
ment among myocilin from different species as well as with
other members of the olfactomedin family of human proteins
(olfactomedin-1 and optimedin) showed that the two novel
mutations affected highly conserved amino acid residues
(Arg346 and Tyr479), which are located in two regions of pre-
dicted beta-sheet folding (Figure 3). In addition, the two novel
non-conservative mutations altered the predicted physico-
chemical properties of the polypeptide chain. The positive
charge of Arg at position 346 is substituted by the polar Thr
side chain in the mutant protein. Similarly, the hydrophobic
Tyr is replaced by the polar His residue at amino acid position
479. These predicted amino acid changes could disrupt the
secondary structure of myocilin, resulting in protein
misfolding.
Transient expression of the two novel missense myocilin
mutants in 293T cells showed that they accumulated intracel-
lularly, mainly in the insoluble cellular fraction (Figure 4).
The same behavior was observed with the myocilin mutation,
Pro370Leu, which was used as a control because it is associ-
ated with one of the most severe myocilin glaucoma pheno-
types [31]. A 35 kDa myocilin fragment was present in the
culture medium of cells expressing wild-type myocilin (Fig-
ure 4, culture medium lanes), which is produced by proteolytic
cleavage of the protein [25]. This fragment was neither de-
tected in the two myocilin mutants nor in the control muta-
tion, Pro370Leu (Figure 4), indicating that the proteolytic pro-
cessing is reduced by these mutations, as previously described
for myocilin pathogenic mutations [25].
Immunocytochemical analysis of the two novel mutant
myocilins transiently expressed in 293T cells revealed intense
granular signals in the cytoplasm (Figure 5B and Figure 5C).
This indicates most of the mutant myocilins accumulated in-
tracellularly in the ER as misfolded proteins. This staining
pattern clearly contrasted with that of wild-type myocilin,
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Figure 4. Western immunoblot of two novel myocilin mutations found
in this study and expressed in transiently transfected 293T cells.  Two
hundred nanograms of DNA constructs encoding myc epitope-tagged
versions of mutant myocilin forms (Arg346Thr, Tyr479His,
Gln368Stop and Pro370Leu) were transfected into 293T cells. Sepa-
ration of culture medium, soluble cellular fractions, and insoluble
cellular fractions were carried out as indicated in the Materials and
Methods. Detection was performed with an anti-myc monoclonal
antibody. Myc-tagged wild-type myocilin was used as a control of
normal expression and the myocilin mutation Pro370Leu was em-
ployed as a control of disease-causing mutation. The arrow and ar-
rowhead indicate the position of the 55 kDa and 35 kDa myocilin
bands, respectively. c.m.: culture medium; s.c.f.: soluble cellular frac-
tion; i.c.f.: insoluble cellular fraction.
Figure 5. Subcellular distribu-
tion in transiently transfected
293T cells of human wild-type
myocilin-GFP and two novel
myocilin mutations found in
this study.  Two hundred nano-
grams of DNA constructs en-
coding wild-type myocilin (A),
mutant myocilin forms,
Arg346Thr (B) and Tyr479His
(C), and the control,
Pro370Leu (a disease causing
mutation; D) were transfected
into 293T cells. Wild-type
myocilin was mainly detected
in structures compatible with
the Golgi apparatus and secre-
tory vesicles. Note that the
three mutant versions accumu-
lated in the ER. The asterisk
indicates the location of the
Golgi apparatus. Arrows indi-
cate the position of intracellu-
lar myocilin aggregates. Origi-
nal magnification: X1600.
868which was distributed in a reticular network located around
the nucleus and cytoplasm and labeled a perinuclear structure
compatible with the Golgi apparatus (Figure 5A). These re-
sults agree with previous reports [25,32-36] and strongly sup-
port that the two novel mutations found in the glaucoma pa-
tients are pathogenic.
Analysis of optineurin sequence variations in sporadic
cases of primary open-angle glaucoma: To evaluate the role
of OPTN DNA sequence variations in Spanish patients affected
by POAG, we screened the complete coding region of the gene
in cases and controls by SSCP. Analysis by PCR DNA se-
quencing of the SSCP positive samples revealed two different
G>A transitions, which originated two synonymous SNPs:
Thr34Thr and Leu41Leu (Table 9). Both SNPs mapped to exon
4 and have been previously described in other populations
[18,37-40]. Thr34Thr is a common polymorphism in our popu-
lation, whereas Leu41Leu is a relatively rare one with MAFs
of 1.8% and 2.6% in POAG and controls, respectively (Table
9). The low frequency allele (A) was not detected in the OHT
group. Their genotype frequencies are shown in Table 10. There
were no statistically significant differences in either allele or
genotype frequencies between cases and controls (Table 8 and
Table 9). These data indicate that OPTN DNA sequence varia-
tions are not involved in high-pressure POAG in the Spanish
population.
DISCUSSION
 Information regarding the role of MYOC and OPTN in Span-
ish POAG patients is scarce. So, the contribution of OPTN
sequence variations to POAG in Spain has not been analyzed
so far. Therefore, the main purpose of this study was to ana-
lyze the contribution of MYOC and OPTN sequence varia-
tions to adult-onset glaucoma in patients from this country.
We have found that heterozygous glaucoma MYOC mu-
tations are located in the olfactomedin-like domain in 2.7% of
POAG patients from Southeast Spain in accordance with fre-
quencies reported in other populations [9,29]. One of the most
interesting findings of this study was the identification of the
novel mutation Tyr479His in an early-onset glaucoma patient
with a mild phenotype. The high evolutionary conservation of
the affected amino acid residue together with the biochemical
and microscopy analysis supports the pathogenicity of this mu-
tation. Two of the identified mutations, Gln368Stop and
Ala445Val, have been previously described. Gln368Stop is
the most common myocilin mutation found in POAG [8,29].
Interestingly, it is generally associated with late glaucoma onset
(mean age at diagnosis 54.9 years) and low IOPs compared to
other MYOC mutations [41]. Carriers of this mutation also
show adequate responses to medical treatment similar to ordi-
nary adult-onset POAG patients [8,9,29,30,41,42]. In contrast,
our study found that Gln368Stop was associated with severe
optic disk and visual damage and the patient who carried the
mutation required surgery for a correct control of IOP. Since
diagnosis was performed timely (at 56 years) further work is
necessary to determine whether the phenotype is directly
caused by this mutation or if it is influenced by other genetic
and/or environmental factors.
Mutation Ala445Val has been previously found in OHT
[43] and POAG patients from different populations [8,44]. The
case subject who harboured this predicted amino acid sub-
stitution (number 50) showed a mild glaucoma phenotype.
Noteworthy, a second novel mutation, Arg346Thr, was found
in a patient with a narrow-angle. For this reason, it was not
considered as a mutation found in POAG patients. Interest-
ingly, this subject was diagnosed with glaucoma at 44 years
of age, in contrast with typical closure-angle glaucoma which
usually manifests at older ages. Preventive iridotomy to pre-
vent pupillary block, followed by medical treatment with three
drugs were not sufficient to reduce IOP thus required filtra-
tion surgery. These data indicate that the narrow angle is not
the primary cause of glaucoma in this patient. Furthermore, it
has been reported that myocilin mutations are not associated
with angle-closure glaucoma, at least in Chinese patients [45].
Altogether, these data suggest that the narrow angle and the
myocilin mutation could be coincidental in this patient and
that Tyr479His could be involved in POAG development.
Further investigations are required to determine the exact role
of this mutation in POAG.
A previous study identified 7.5% of MYOC mutation car-
riers in patients from Galicia (N. Spain), but only sequence
variations in exon 3 were analyzed [46]. Apart from
Gln368Stop, which has also been identified by Vazquez and
co-workers, the spectrum of pathogenic mutations was differ-
ent from that found in the present study. It remains to be in-
vestigated whether these differences can be attributed to dif-
ferent genetic backgrounds between these two Spanish sub-
populations or to the sample size used in the two studies. The
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TABLE 9. ALLELE FREQUENCIES OF OPTINEURIN SINGLE NUCLEOTIDE
POLYMORPHISMS IN PRIMARY OPEN-ANGLE GLAUCOMA, ADULT-ONSET
OCULAR HYPERTENSION, AND CONTROL SUBJECTS
                               POAG (%)   OHT (%)   CONTROL (%)
   Polymorphism       Allele   (n=220)    (n=80)      (n=196)      p*     p#
-------------------   ------   --------   -------   -----------   ----   ----
c.412G>A (Thr34Thr)     G        66.4      75.00       65.3       0.82   0.11
                        A        33.6      25.00       34.7
c.433G>A (Leu41Leu)     G        98.2     100.00       97.4       0.74   0.32
                        A         1.8       0.00        2.6
A χ2 test or Fisher’s exact test was used to compare allele frequen-
cies in POAG or OHT patients with control subjects. Allele frequen-
cies do not statistically differ between cases and controls. The aster-
isk indicates POAG versus controls and the sharp (hash mark) indi-
cates OHT versus controls.
TABLE 10. GENOTYPE FREQUENCIES OF OPTINEURIN SINGLE NUCLE-
OTIDE POLYMORPHISMS IN PRIMARY OPEN-ANGLE GLAUCOMA, ADULT-
ONSET OCULAR HYPERTENSION, AND CONTROL SUBJECTS
                      Allele1/   POAG (%)   OHT (%)   CONTROL (%)
        SNP           Allele2    (n=110)    (n=40)      (n=98)       p*     p#
-------------------   --------   --------   -------   -----------   ----   ----
c.412G>A (Thr34Thr)     G/G        44.3       56.6       49.9       0.06   0.20
                        G/A        44.3       36.6       31.0
                        A/A        11.4        6.6       19.0
c.433G>A (Leu41Leu)     G/G        98.2      100.0       94.6       0.25   0.32
                        G/A         1.8        0.0        5.3
                        A/A         0.0        0.0        0.0
A χ2 test or Fisher’s exact test was used to compare genotype fre-
quencies in POAG or OHT patients with control subjects. Genotype
frequencies do not statistically differ between cases and controls.
The asterisk indicates POAG versus controls and the sharp (hash
mark) indicates OHT versus controls.
869same researchers later analyzed MYOC mutations in exons 1
and 2 and in the promoter region of this group of patients. No
mutations in these two exons were found, and although five
sequence variations were identified in the promoter region,
no association with the disease was established [47], which
agrees with our results.
In a previous study we found that approximately 10% of
Spanish POAG patients carry mutations in the CYP1B1 gene
[17], which is three times higher than the frequency of carri-
ers of mutations in the MYOC gene. This data clearly shows
the existence of genetic heterogeneity among Spanish POAG
patients and indicates that CYP1B1 sequence alterations are
the most important genetically known cause of POAG, at least
in our population.
In the present study we have identified 15 MYOC SNPs,
one polymorphic GT microsatellite, and one 28 bp insertion.
All these DNA sequence variations were distributed along the
promoter and coding region of the gene. To the best of our
knowledge, three of these SNPs (-315G>A, -190G>T, and
Leu166Leu) and the -700_699ins have been identified here
for the first time. None of the polymorphic DNA sequence
variations showed significant association with glaucoma. Al-
beit some of these promoter SNPs were located in putative
regulatory promoter sequences, it remains to be demonstrated
whether they affect MYOC expression. In any event, it is un-
likely that changes in the gene expression may contribute to
myocilin glaucoma since development of the disease appears
to be related with structural alterations of the protein [34,48,49].
In accordance with previous reports, we found that allele
and genotype frequencies of SNP -1000C>G were not signifi-
cantly different in cases and controls [50-52]. Since Colomb
et al reported the association of this SNP with the severity of
POAG, there has been some controversy about the actual re-
lationship with the disease. Our data support that there is no
association between this polymorphism and the disease in
Spanish patients.
We detected two LD blocks composed of SNPs -1000C>G
and -387C>T (block 1) and -83G>A and Arg76Lys (block 2).
LD block 1 has been described in the Chinese population [53]
whereas LD block 2 has been found in Asian [53-58] and Eu-
ropean populations [10]. Analysis of inferred six loci
haplotypes further confirmed no association of MYOC pro-
moter polymorphisms with either OHT or POAG in the stud-
ied Spanish population.
Defects in OPTN have been clearly implicated in normal
tension glaucoma (NTG) [18,40], but its role in high-pressure
glaucoma has been a source of controversy [59-61]. In accor-
dance with previous reports, our data indicate that OPTN does
not contribute to the development of either OHT or typical
adult-onset high-pressure glaucoma, at least in the Spanish
population [62].
The present study provides new insight into the role of
MYOC and OPTN genes in POAG in Spain and brings new
information to unravel genetic alterations associated with
POAG in this country.
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